Crucell, DSM Biologics license cell line to IQ for anthrax antibodies

New York, Oct. 19 - Crucell NV and allied contract manufacturer DSM Biologics said they have agreed to license for IQ Corp. to evaluate and use their PER.C6 cell line for production of monoclonal antibodies.

IQ will use PER.C6 to manufacture its proprietary anti-anthrax antibodies.

"Crucell's human PER.C6 production platform is a good match with our technology as it keeps our Immunity from a Vial antibodies fully human from generation to the end product," said Herman Groen, IQ's chief scientific officer, in a news release.

IQ will pay an undisclosed signing fee and annual maintenance fees, also undisclosed.

Crucell is a Leiden, Netherlands, biotechnology company working on vaccines and antibodies for infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies.

DSM Biologics is a contract manufacturer of biopharmaceutical products based in Groningen, Netherlands.

IQ is a Groningen, Netherlands, life sciences company working on the use of antibodies for diagnostic and therapeutic applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.